Hsiao D. Lieu - 06 Nov 2023 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC

Role
EVP, Chief Medical Officer
Signature
/s/ Valerie Pierce, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
06 Nov 2023
Net transactions value
$0
Form type
4
Filing time
08 Nov 2023, 18:08:22 UTC
Previous filing
06 Mar 2023
Next filing
18 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Award +190,000 190,000 06 Nov 2023 Common Stock 190,000 $0.8400 Direct F1, F2
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -190,000 -100% 0 06 Nov 2023 Common Stock 190,000 $12.06 Direct F1, F2
transaction NGM Stock Option (Right to Buy) Award +25,000 25,000 06 Nov 2023 Common Stock 25,000 $0.8400 Direct F2, F3
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -25,000 -100% 0 06 Nov 2023 Common Stock 25,000 $16.47 Direct F2, F3
transaction NGM Stock Option (Right to Buy) Award +100,000 100,000 06 Nov 2023 Common Stock 100,000 $0.8400 Direct F2, F4
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -100,000 -100% 0 06 Nov 2023 Common Stock 100,000 $31.93 Direct F2, F4
transaction NGM Stock Option (Right to Buy) Award +150,000 150,000 06 Nov 2023 Common Stock 150,000 $0.8400 Direct F2, F5
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -150,000 -100% 0 06 Nov 2023 Common Stock 150,000 $15.20 Direct F2, F5
transaction NGM Stock Option (Right to Buy) Award +150,000 150,000 06 Nov 2023 Common Stock 150,000 $0.8400 Direct F2, F6
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -150,000 -100% 0 06 Nov 2023 Common Stock 150,000 $5.36 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested.
F2 Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the "Company") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged.
F3 The shares subject to the stock option vest over a four-year period commencing January 1, 2020, with 1/48th of the shares vesting on a monthly basis.
F4 The shares subject to the stock option vest over a four-year period commencing January 1, 2021, with 1/48th of the shares vesting on a monthly basis.
F5 The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis.
F6 The shares subject to the stock option vest over a two-year period commencing November 4, 2022, with 1/2 of the shares vesting on an annual basis.